SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 13th, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April , 2017, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • April 13th, 2017 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:Letter Agreement • April 13th, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:DelMar Pharmaceuticals, Inc. • April 13th, 2017 • Pharmaceutical preparations
This letter shall serve as an amendment (the “Amendment”) to that certain engagement letter (the “Original Letter”), dated as of January 24, 2017, by and between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Original Letter.
STRICTLY CONFIDENTIALDelMar Pharmaceuticals, Inc. • April 13th, 2017 • Pharmaceutical preparations
This letter shall serve as an amendment (the “Amendment”) to that certain engagement letter, dated as of January 24, 2017, as amended on February 21, 2017 (the “Original Letter”), by and between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Original Letter.
